Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.
Dr. de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015.
His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing in breast cancer) such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer) and – in the neoadjuvant setting - the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO).
Dr. de Azambuja was a member of the ESMO Executive Board (2018), and currently is an ESMO Council Member (since 2019) and the Chair of the ESMO Fellowship Committee (mandate started in January 2018). He was a member of the ESMO Young Oncologists Committee (YOC) and the ESMO Press & Media Affairs Committee. He is also a faculty member of the ESMO Leaders Generation Program launched in 2016-2017 and Co-Chair of this Programme since 2018. He was appointed as the Chair of the ESMO Leadership Generation Task Force in January 2019. He was appointed as a Breast Faculty Member of ESMO in 2017 and was a Board Member of the Belgian Society of Medical Oncology (BSMO) 2015-2019.
Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the Belgian Society of Medical Oncology (BSMO). He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspectives.
He has (co)-authored about 210 peer-reviewed articles and 15 book chapters. He has been a member of Education and Scientific Committees of the ESMO, ESMO Breast, EBCC and ECCO meetings.
Last update: October 2020